[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$HIMS Hims & Hers Health Q3 2025 Earnings Summary Q3 Results: EPS: $XXXX miss by $XXXX (vs. $XXXX consensus) Revenue: $598.98M up XXXX% YoY beat vs. $580.24M consensus Guidance: Q4 Revenue: $605625M (below $631.69M consensus) Q4 Adj. EBITDA: $5565M Strategic Update: Novo Nordisk Partnership Talks: Hims & Hers is in active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy (pending FDA approval) available via its platform. The collaboration aims to expand consumer access to GLP-1 treatments under prescriber guidance. The company clarified that no definitive agreement has"
X Link @tenet_research 2025-11-03T21:12Z 452.2K followers, 1234 engagements
"$HIMS Q3 Earnings Report is out. Revenue of $599M vs. $579.9M est. 🟢 Adj. EBITDA of $78.4M vs. $68M est. 🟢 EPS of $XXXX vs. $XXXX est. 🔴 Free Cash Flow of $79.4M flat YoY Q4 Revenue guidance of $605-625M vs. $629.6M est. 🔴 Q4 Adj. EBITDA guidance of $55-65M vs. $75.6M est. 🔴 Lowers FY2025 Revenue guidance to $2.335-2.355B vs. $2.342B est. 🟡 Narrows FY2025 Adj. EBITDA guidance to $307-317M vs. $316.9M est. 🔴"
X Link @mvcinvesting 2025-11-03T21:08Z 78K followers, 78.6K engagements